Misplaced Pages

Medicines for Malaria Venture

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
This article contains promotional content. Please help improve it by removing promotional language and inappropriate external links, and by adding encyclopedic text written from a neutral point of view. (May 2018) (Learn how and when to remove this message)
This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.
Find sources: "Medicines for Malaria Venture" – news · newspapers · books · scholar · JSTOR (September 2012) (Learn how and when to remove this message)
(Learn how and when to remove this message)

Medicines for Malaria Venture (MMV) is a not-for-profit public-private partnership that was established as a foundation in Switzerland in 1999. Its main mission is to reduce malaria in disease-endemic countries by developing and facilitating the delivery of antimalarial drugs.

History

MMV was launched in 1999, with initial seed funding of US$4 million from the Government of Switzerland, the Department for International Development (UK), the Government of the Netherlands, the World Bank, and the Rockefeller Foundation.

Governance

MMV is governed by a board of directors. The Chairman of MMV is Mr Alan Court. MMV has a board of directors in North America, an Expert Scientific Advisory Committee which helps to identify projects, an Access & Product Management Advisory Committee and a Global Safety Board which reviews projects.

Projects

MMV's project portfolio states that their goals are:

  • Effective treatment against drug-resistant strains of Plasmodium falciparum
  • The potential for intermittent treatments (infants and pregnancy)
  • Safety for small children (less than 6 months old)
  • Safety in pregnancy
  • Effective treatment against Plasmodium vivax (including radical cure)
  • Effective treatment against severe malaria
  • and transmission-blocking treatment.

Open Source Malaria

MMV started the Open Source Malaria project, which encourages people to share procedures and results of open source research. The Open Source Malaria, with researchers at the University of Sydney, supervised high school students at Sydney Grammar School who adapted a synthesis of Daraprim (pyrimethamine) using a less hazardous method.

References

  1. "Board of Directors | Medicines for Malaria Venture". www.mmv.org. Archived from the original on 1 May 2024. Retrieved 12 December 2022.
  2. "People & governance | Medicines for Malaria Venture". www.mmv.org. Archived from the original on 1 May 2024. Retrieved 12 December 2022.
  3. "OpenSourceMalaria". OpenWetWare. 14 May 2017.
  4. "OpenSourceMalaria:FAQ". OpenWetWare.
  5. University of Sydney (30 November 2016). "Breaking good: School students make costly drug cheaply using open source approach". Eurekalert.
  6. Knopf, Ehsan (1 December 2016). "Sydney high school students spend $27 to recreate drug that has retailed for $148k". 9news.com.au.

External links

Malaria
Biology
Control and prevention
Diagnosis and treatment
Society and malaria
Organisations
Category
Categories: